Related Experiment Video

Updated: Feb 1, 2026

Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

19.8K

Trial Watch: Toll-like receptor agonists in cancer immunotherapy

Melody Smith1, Elena García-Martínez2, Michael R Pitter1

  • 1Department of Medicine and Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Oncoimmunology
|December 8, 2018
PubMed

Insights

Toll-like receptor (TLR) agonists show promise as immunotherapy adjuvants for cancer treatment. Recent research highlights advances in developing these TLR ligands for clinical use in cancer therapy.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Toll-like receptor (TLR) agonists are investigated as immunological adjuvants for cancer immunotherapy.
  • Three TLR agonists are currently approved by US regulatory agencies for cancer treatment.
  • Experimental TLR ligands are being studied for their potential to stimulate immune responses against cancer.

Purpose of the Study:

  • To summarize recent preclinical and clinical advances in the development of TLR agonists for cancer therapy.

Main Methods:

  • Review of preclinical studies on TLR agonists in cancer models.
  • Analysis of clinical trial data for TLR agonists in cancer patients.
  • Synthesis of current research on TLR ligand development for immunotherapy.

Main Results:

  • Several TLR agonists have shown therapeutic promise in preclinical and clinical settings.
  • Ongoing research is expanding the range of TLR ligands investigated for cancer treatment.
  • Advances in understanding TLR signaling pathways are driving new therapeutic strategies.

Conclusions:

  • TLR agonists represent a promising class of agents for anticancer immunotherapy.
  • Continued research and clinical development are crucial for realizing the full potential of TLR agonists.
  • TLR-targeted therapies offer a valuable approach to enhancing the efficacy of cancer treatment.
Keywords:
Ampligen®Hiltonol®SD-101bacillus Calmette-Guérinimiquimodmotolimod

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.0K
Isolation of Murine Peritoneal Macrophages to Carry Out Gene Expression Analysis Upon Toll-like Receptors Stimulation08:21

Isolation of Murine Peritoneal Macrophages to Carry Out Gene Expression Analysis Upon Toll-like Receptors Stimulation

Published on: April 29, 2015

38.1K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
964
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.1K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
994
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
508
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.9K